Davit L Aghayan1,2, Airazat M Kazaryan3,4, Åsmund Avdem Fretland3,5,6, Mushegh A Sahakyan3,6, Bård I Røsok5, Bjørn Atle Bjørnbeth5, Bjørn Edwin3,5,6. 1. The Intervention Centre, Oslo University Hospital - Rikshospitalet, Pb. 4950 Nydalen, 0424, Oslo, Norway. dr.aghayan@gmail.com. 2. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. dr.aghayan@gmail.com. 3. The Intervention Centre, Oslo University Hospital - Rikshospitalet, Pb. 4950 Nydalen, 0424, Oslo, Norway. 4. Department of Gastrointestinal Surgery, Akershus University Hospital, Lørenskog, Norway. 5. Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway. 6. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: Stage IV metastatic melanoma carries a poor prognosis. In the case of melanoma liver metastasis (MLM), surgical resection may improve survival and represents a therapeutic option, with varying levels of success. Laparoscopic liver resection (LLR) for metastatic melanoma is poorly studied. The aim of this study was to analyze the outcomes of LLR in patients with MLM. MATERIALS AND METHODS: Between April 2000 and August 2013, 11 (1 cutaneous, 9 ocular and 1 unknown primary) patients underwent LLR for MLM at Oslo University Hospital-Rikshospitalet and 13 procedures in total were carried out. Perioperative and oncologic outcomes were analyzed. Postoperative morbidity was classified using the Accordion classification. Kaplan-Meier method was used for survival analysis. RESULTS: A total of 23 liver specimens were resected. The median operative time was 137 (65-470) min, while the median blood loss was less than 50 (<50-900) ml. No intraoperative unfavorable incidents and 30-day mortality occurred. Median follow-up was 33 (9-92) months. Ten patients (91%) developed recurrence within a median of 5 months (2-18 months) and two patients underwent repeat LLR for recurrent liver metastases. One-, three-, and five-year overall survival rates were 82, 45 and 9%, respectively. The median overall survival was 30 (9-92) months. CONCLUSION: Perioperative morbidity and long-term survival after LLR for MLM seems to be comparable to open liver resection. Thus, LLR may be preferred over open liver resection due to the well-known advantages of laparoscopy, such as reduced pain and improved possibility for repeated resections.
BACKGROUND: Stage IV metastatic melanoma carries a poor prognosis. In the case of melanoma liver metastasis (MLM), surgical resection may improve survival and represents a therapeutic option, with varying levels of success. Laparoscopic liver resection (LLR) for metastatic melanoma is poorly studied. The aim of this study was to analyze the outcomes of LLR in patients with MLM. MATERIALS AND METHODS: Between April 2000 and August 2013, 11 (1 cutaneous, 9 ocular and 1 unknown primary) patients underwent LLR for MLM at Oslo University Hospital-Rikshospitalet and 13 procedures in total were carried out. Perioperative and oncologic outcomes were analyzed. Postoperative morbidity was classified using the Accordion classification. Kaplan-Meier method was used for survival analysis. RESULTS: A total of 23 liver specimens were resected. The median operative time was 137 (65-470) min, while the median blood loss was less than 50 (<50-900) ml. No intraoperative unfavorable incidents and 30-day mortality occurred. Median follow-up was 33 (9-92) months. Ten patients (91%) developed recurrence within a median of 5 months (2-18 months) and two patients underwent repeat LLR for recurrent liver metastases. One-, three-, and five-year overall survival rates were 82, 45 and 9%, respectively. The median overall survival was 30 (9-92) months. CONCLUSION: Perioperative morbidity and long-term survival after LLR for MLM seems to be comparable to open liver resection. Thus, LLR may be preferred over open liver resection due to the well-known advantages of laparoscopy, such as reduced pain and improved possibility for repeated resections.
Authors: R J Salmon; C Levy; C Plancher; T Dorval; L Desjardins; S Leyvraz; P Pouillart; P Schlienger; V Servois; B Asselain Journal: Eur J Surg Oncol Date: 1998-04 Impact factor: 4.424
Authors: D Gomez; C Wetherill; J Cheong; L Jones; E Marshall; B Damato; S E Coupland; P Ghaneh; G J Poston; H Z Malik; S W Fenwick Journal: J Surg Oncol Date: 2013-12-19 Impact factor: 3.454
Authors: A Y Bedikian; S S Legha; G Mavligit; C H Carrasco; S Khorana; C Plager; N Papadopoulos; R S Benjamin Journal: Cancer Date: 1995-11-01 Impact factor: 6.860
Authors: Stavros A Antoniou; Sofia Tsokani; Dimitrios Mavridis; Ferdinando Agresta; Manuel López-Cano; Filip E Muysoms; Salvador Morales-Conde; Hendrik-Jaap Bonjer; Thérèse van Veldhoven; Nader K Francis Journal: Surg Endosc Date: 2020-04-02 Impact factor: 4.584
Authors: Katharina M Schmidt; Peter Dietrich; Christina Hackl; Jessica Guenzle; Peter Bronsert; Christine Wagner; Stefan Fichtner-Feigl; Hans J Schlitt; Edward K Geissler; Claus Hellerbrand; Sven A Lang Journal: Neoplasia Date: 2018-11-04 Impact factor: 5.715
Authors: C L A Dewald; L S Becker; S K Maschke; T C Meine; T A Alten; M M Kirstein; A Vogel; F K Wacker; B C Meyer; J B Hinrichs Journal: Clin Exp Metastasis Date: 2020-10-09 Impact factor: 5.150